Xilio Therapeutics (XLO) Capital Expenditures (2020 - 2026)

Xilio Therapeutics has disclosed Capital Expenditures across 7 years of filings, most recently posting $19000.0 for Q2 2026.

• In Q2 2026, Capital Expenditures fell 85.5% year-over-year to $19000.0; the TTM figure through Jun 2026 stood at $670000.0 (up 52.97% YoY), while the FY2025 annual figure was $518000.0, up 1338.89% from the prior year.
• Capital Expenditures came in at $19000.0 for Q2 2026 at Xilio Therapeutics, down from $556000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $771000.0 in Q2 2022 to a low of $6000.0 in Q4 2024.
• Average Capital Expenditures over 5 years is $248714.3, with a median of $215000.0 recorded in 2022.
• Year-over-year, Capital Expenditures plunged 93.23% in 2024 and jumped 1483.33% in 2025.
• Over 5 years, Capital Expenditures stood at $509000.0 in 2022, then plunged by 65.42% to $176000.0 in 2023, then tumbled by 96.59% to $6000.0 in 2024, then jumped by 1483.33% to $95000.0 in 2025, then sank by 80.0% to $19000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $19000.0 in Q2 2026, $556000.0 in Q1 2026, and $95000.0 in Q4 2025.